Biotech/Medical Tech Stock News from Investorideas.com

Monday, April 8, 2024

Are Biotech Stocks the Cure for Today’s Investors? (TSX: $AIDX.TO) (Nasdaq: $XFOR) (Nasdaq: $RCKT) (NYSE: $AUNA)

Are Biotech Stocks the Cure for Today’s Investors? (TSX: $AIDX.TO) (Nasdaq: $XFOR) (Nasdaq: $RCKT) (NYSE: $AUNA)

April 8, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech/Life Sciences sectors.

Read this in full at: https://www.investorideas.com/news/2024/main/04082Stocks.asp

The newest biotech companies are involved in preventative care, immune system disease, gene therapy for the treatment of rare, complex diseases and a Latin American healthcare company.

New Stocks Added to the Biotech Directories:

HEALWELL AI Inc. (OTCQX: HWAIF) (TSX: AIDX) is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map.

X4 Pharmaceuticals, Inc. (Nasdaq:XFOR) is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a selective, small-molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of immunodeficiencies, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and certain chronic neutropenic disorders. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. regulatory approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria.

Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.

AUNA S.A. (NYSE:AUNA) is a Latin American healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish Speaking Americas. Founded in 1989, Auna has built one of Latin America´s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of December 31, 2023, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.3 million healthcare plans

Research more biotech stocks with Investorideas Biotech stock directory

https://www.investorideas.com/BIS/Stock_List.asp

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

800 665 0411

Friday, April 5, 2024

Biotech Stock News Bite - Candel Therapeutics, Inc. (Nasdaq: CADL) Big Gains on News of Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409

Biotech Stock News Bite - Candel Therapeutics, Inc. (Nasdaq: CADL) Big Gains on News of Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409: Biotech Stock News Bite - Candel Therapeutics, Inc. (Nasdaq: CADL) Big Gains on News of Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409

Biotech Sector a Healthy Choice for Investors? (Nasdaq: $ELTX) (Nasdaq: $VRDN) (Nasdaq: $KZIA) (Nasdaq: $RGLS)

Biotech Sector a Healthy Choice for Investors? (Nasdaq: $ELTX) (Nasdaq: $VRDN) (Nasdaq: $KZIA) (Nasdaq: $RGLS)

Focus on Life Sciences; (Nasdaq: $AUVI) (CSE: $BETR.CN) (OTC: $FLHLF) (NASDAQ: $OTRK)

April 5, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech/Life Sciences sector.

Read this in full at: https://www.investorideas.com/news/2024/main/04051Stocks.asp

The newest biotech companies offer therapies for cancer, eye disease and microRNA.

The latest life sciences companies work in the fields of smart building tech for healthcare facilities, neuro-psychiatric treatment, psychedelic drug development and AI and telehealth-enabled healthcare.

New Stocks Added to the Biotech Directories:

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.

Viridian Therapeutics, Inc. (Nasdaq:VRDN) is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Kazia Therapeutics (Nasdaq:KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, is ongoing, with final data expected in 1H2024. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study is ongoing and preliminary data is anticipated in CY2024.

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Applied UV, Inc. (Nasdaq: AUVI) is dedicated to developing and acquiring smart building technologies for healthcare, hospitality, commercial and municipal markets. With SteriLumen, MunnWorks, LED Supply Co., and PURO, the company has a diverse portfolio that addresses various needs in the market. Applied UV Inc. is committed to innovation and excellence in providing solutions for a healthier and smarter world.

A BetterLife Pharma (CSE:BETR; OTC: BETRF) is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

Filament Health (NEO:FH; OTC:FLHLF) is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates.

Ontrak, Inc. (NASDAQ: OTRK) is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Research more biotech stocks with Investorideas Biotech stock directory

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com - Big Investing Ideas

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

800 665 0411

Thursday, March 28, 2024

Biotech Stock News Bite - Avalo Therapeutics, Inc. (NASDAQ: AVTX) Makes NASDAQ Top Gainers List on News it acquired Phase 2-ready anti-IL-1β mAb

Biotech Stock News Bite - Avalo Therapeutics, Inc. (NASDAQ: AVTX) Makes NASDAQ Top Gainers List on News it acquired Phase 2-ready anti-IL-1β mAb: Biotech Stock News Bite - Avalo Therapeutics, Inc. (NASDAQ: AVTX) Makes NASDAQ Top Gainers List on News it acquired Phase 2-ready anti-IL-1β mAb

Wednesday, March 27, 2024

Biotech Stock News Bite - Stoke Therapeutics, Inc. (Nasdaq: STOK) Soars on Landmark New Data That Supports Potential for STK-001

Biotech Stock News Bite - Stoke Therapeutics, Inc. (Nasdaq: STOK) Soars on Landmark New Data That Supports Potential for STK-001: Biotech Stock News Bite - Stoke Therapeutics, Inc. (Nasdaq: STOK) Soars on Landmark New Data That Supports Potential for STK-001

Wednesday, March 20, 2024

Doctor’s Orders-Biotech Stocks to Watch (NASDAQ: $LVTX) (NASDAQ: $NKGN) (Nasdaq: $KNSA) (Nasdaq: $GOSS)

Doctor’s Orders-Biotech Stocks to Watch (NASDAQ: $LVTX) (NASDAQ: $NKGN) (Nasdaq: $KNSA) (Nasdaq: $GOSS)

Life Sciences Stocks to Watch: (OTCPink: $MRDH) (NASDAQ: $PBM) (OTCQB: $KRBP) (NASDAQ: $OCEA)

March 20, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech/Life Sciences sector.

Read this in full at: https://www.investorideas.com/news/2024/main/03201Stocks.asp

The newest biotech companies are involved in immuno-oncology, cell therapeutics and biopharmaceuticals.

The latest life sciences companies are involved in developing scientifically compelling assets from research universities, biotherapeutics, natural psychedelics and management services for healthcare settings.

New Stocks Added to the Biotech Directories:

LAVA Therapeutics N.V. (NASDAQ: LVTX) is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.

NKGen Biotech, Inc. (NASDAQ: NKGN) is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. NKGen is headquartered in Santa Ana, California, USA.

Kiniksa Pharmaceuticals (Nasdaq:KNSA) is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation.

Gossamer Bio (Nasdaq:GOSS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.

Ocean Biomedical, Inc. (NASDAQ: OCEA) is a Providence, Rhode Island-based biopharma company with an innovative business model that strives to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical intends to deploy the resources and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic to the world. Ocean Biomedical is currently developing five discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team’s goal is to work on solving some of the world’s toughest problems, for the people who need it most.

Kiromic BioPharma, Inc. (OTCQB: KRBP) is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas.

Psyence Biomedical Ltd (NASDAQ:PBM) is a life science biotechnology company with a focus on natural psychedelics. Psyence Biomed works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. Our name "Psyence" combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.

Meridian Holdings, Inc. (OTCPink: MRDH) is in the business of acquisition-oriented holding company focused on building, operating, and managing a portfolio of business-to-business companies. It seeks to acquire majority or controlling interests in companies, which will allow the holding company to actively participate in management, operations, and finances. The Company's network of affiliated companies is designed to encourage maximum leverage of information technology, operational excellence, industry expertise, and synergistic business opportunities. Meridian Holdings, Inc., provides management services and support to the following business units: InterCare Rx, Dozie and Dozie's Pharma and Meridian Health Systems ACO Corporation (“MHSACO”) a Multi-National healthcare supply chain and medical services management entity.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Research more biotech stocks with Investorideas Biotech stock directory

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com - Big Investing Ideas

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

800 665 0411

Tuesday, March 19, 2024

Biotech Stock News Bite - Elicio Therapeutics, Inc. (Nasdaq: ELTX) Rises on Funding News

Biotech Stock News Bite - Elicio Therapeutics, Inc. (Nasdaq: ELTX) Rises on Funding News: Biotech Stock News Bite - Elicio Therapeutics, Inc. (Nasdaq: ELTX) Rises on Funding News

Disclaimer

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investorideas.com newswire, breaking biotechnology and pharma news

Monday, April 8, 2024

Friday, April 5, 2024

Thursday, March 28, 2024

Wednesday, March 27, 2024

Wednesday, March 20, 2024

Tuesday, March 19, 2024